The sales are small relative to company size and likely part of pre-arranged 10b5-1 plans following option exercises. Not a material negative signal. Watch for future filings to see if selling continues beyond this cluster.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 6 $559.65entry
- T+1 · 7mo ago +1.08%α +1.04% · $565.70
- T+5 · 7mo ago +3.21%α −0.91% · $577.63
- T+20 · 7mo ago +3.85%α −5.11% · $581.22
- T+60 · 5mo ago −2.23%α −15.41% · $547.15
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three top executives at United Therapeutics, the CEO, CFO, and General Counsel, sold a combined $376K in shares over a 7-day window, following the exercise of stock options. The sales represent less than 0.0015% of the company's $24.8B market cap and appear to be part of pre-planned, non-discretionary transactions following option exercises.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt sold $21.7K, CFO James Edgemon sold $66.3K, and General Counsel Paul Mahon sold $288K in open-market transactions.
- All sales followed the exercise of stock options, with significant non-cash derivative exercises totaling over $5.4M in option value realized.
- Total dollar value of open-market sales ($376K) is only 0.0015% of the company's $24.8B market cap.
- Sales occurred at prices between $551.86 and $560.30 per share.
Financial Impact
$376,000 in net insider selling
Risk Factors
- Perception of insider pessimism if media or retail investors misinterpret routine transactions.
- Potential for increased scrutiny if similar clusters recur in the near term.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1775680472985 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers